Literature DB >> 1885750

Cross-reactive antibodies induced by a monovalent influenza B virus vaccine.

R A Levandowski1, P A Gross, M Weksler, E Staton, M S Williams, J Bonelli.   

Abstract

Influenza viruses related to the markedly antigenically divergent strains B/Yamagata/16/88 and B/Victoria/2/87 are circulating in human populations. Adults develop cross-reacting antibodies against recent and earlier influenza B virus strains after vaccination with B/Yamagata/16/88, probably because of previous influenza B virus infections or immunizations. Vaccines containing B/Yamagata/16/88 should adequately protect adults against B/Victoria/2/87 infections.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1885750      PMCID： PMC270149          DOI： 10.1128/jcm.29.7.1530-1532.1991

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  9 in total

1.  Influence of primary antigenic experience upon the development of a broad immunity to influenza.

Authors:  F M DAVENPORT; A V HENNESSY; T FRANCIS
Journal:  Trans Assoc Am Physicians       Date:  1957

2.  Cocirculation of two distinct evolutionary lineages of influenza type B virus since 1983.

Authors:  P A Rota; T R Wallis; M W Harmon; J S Rota; A P Kendal; K Nerome
Journal:  Virology       Date:  1990-03       Impact factor: 3.616

3.  Improved colorimetric assay for detecting influenza B virus neutralizing antibody responses to vaccination and infection.

Authors:  G A Tannock; J A Paul; R Herd; R D Barry; A L Reid; M J Hensley; R S Gillett; S M Gillett; P Lawrance; R L Henry
Journal:  J Clin Microbiol       Date:  1989-03       Impact factor: 5.948

4.  Antibody response in humans to influenza virus type B host-cell-derived variants after vaccination with standard (egg-derived) vaccine or natural infection.

Authors:  M W Harmon; P A Rota; H H Walls; A P Kendal
Journal:  J Clin Microbiol       Date:  1988-02       Impact factor: 5.948

5.  The hemagglutinin of influenza B virus present in clinical material is a single species identical to that of mammalian cell-grown virus.

Authors:  J S Robertson; J S Bootman; C Nicolson; D Major; E W Robertson; J M Wood
Journal:  Virology       Date:  1990-11       Impact factor: 3.616

6.  Influenza B virus infections in the community and the family. The epidemics of 1976-1977 and 1979-1980 in Houston, Texas.

Authors:  A L Frank; L H Taber; W P Glezen; E A Geyer; S McIlwain; A Paredes
Journal:  Am J Epidemiol       Date:  1983-09       Impact factor: 4.897

7.  Increased sensitivity and reduced specificity of hemagglutination inhibition tests with ether-treated influenza B/Singapore/222/79.

Authors:  A P Kendal; T R Cate
Journal:  J Clin Microbiol       Date:  1983-10       Impact factor: 5.948

8.  Ether treatment of type B influenza virus antigen for the hemagglutination inhibition test.

Authors:  A S Monto; H F Maassab
Journal:  J Clin Microbiol       Date:  1981-01       Impact factor: 5.948

9.  Epidemiologic and immunologic significance of age distribution of antibody to antigenic variants of influenza virus.

Authors:  F M DAVENPORT; A V HENNESSY; T FRANCIS
Journal:  J Exp Med       Date:  1953-12       Impact factor: 14.307
  9 in total
  15 in total

1.  A human immunodeficiency virus prime-boost immunization regimen in humans induces antibodies that show interclade cross-reactivity and neutralize several X4-, R5-, and dualtropic clade B and C primary isolates.

Authors:  F Verrier; S Burda; R Belshe; A M Duliege; J L Excler; M Klein; S Zolla-Pazner
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

2.  Immunogenicity and safety of a cell culture-derived inactivated quadrivalent influenza vaccine (NBP607-QIV): A randomized, double-blind, multi-center, phase III clinical trial in adults and elderly subjects.

Authors:  Won Suk Choi; Ji Yun Noh; Joon Young Song; Hee Jin Cheong; Seong-Heon Wie; Jin Soo Lee; Jacob Lee; Shin-Woo Kim; Hye Won Jeong; Sook-In Jung; Yeon-Sook Kim; Heung Jeong Woo; Kyung Ho Kim; Hun Kim; Woo Joo Kim
Journal:  Hum Vaccin Immunother       Date:  2017-04-13       Impact factor: 3.452

3.  Statement on Seasonal Influenza Vaccine for 2011-2012: An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI)†.

Authors: 
Journal:  Can Commun Dis Rep       Date:  2011-10-14

4.  Statement on Seasonal Trivalent Inactivated Influenza Vaccine (TIV) for 2010-2011: An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI)†.

Authors: 
Journal:  Can Commun Dis Rep       Date:  2010-08-31

5.  STATEMENT ON SEASONAL INFLUENZA VACCINE FOR 2012-2013: An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI).

Authors: 
Journal:  Can Commun Dis Rep       Date:  2012-08-01

6.  Statement on Seasonal Influenza Vaccine for 2013-2014: An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI).

Authors: 
Journal:  Can Commun Dis Rep       Date:  2013-10-10

7.  Heterogeneity of influenza B virus strains in one epidemic season differentiated by monoclonal antibodies and nucleotide sequences.

Authors:  N Nakagawa; R Kubota; A Maeda; T Nakagawa; Y Okuno
Journal:  J Clin Microbiol       Date:  2000-09       Impact factor: 5.948

8.  Cross-lineage influenza B and heterologous influenza A antibody responses in vaccinated mice: immunologic interactions and B/Yamagata dominance.

Authors:  Danuta M Skowronski; Marie-Eve Hamelin; Naveed Z Janjua; Gaston De Serres; Jennifer L Gardy; Chantal Rhéaume; Xavier Bouhy; Guy Boivin
Journal:  PLoS One       Date:  2012-06-22       Impact factor: 3.240

9.  Lineage-specific protection and immune imprinting shape the age distributions of influenza B cases.

Authors:  Marcos C Vieira; Celeste M Donato; Philip Arevalo; Guus F Rimmelzwaan; Timothy Wood; Liza Lopez; Q Sue Huang; Vijaykrishna Dhanasekaran; Katia Koelle; Sarah Cobey
Journal:  Nat Commun       Date:  2021-07-14       Impact factor: 14.919

10.  Matrix-M™ adjuvation broadens protection induced by seasonal trivalent virosomal influenza vaccine.

Authors:  Freek Cox; Eirikur Saeland; Matthijs Baart; Martin Koldijk; Jeroen Tolboom; Liesbeth Dekking; Wouter Koudstaal; Karin Lövgren Bengtsson; Jaap Goudsmit; Katarina Radošević
Journal:  Virol J       Date:  2015-12-08       Impact factor: 4.099
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.